KYMR has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KYMR has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Kymera Therapeutics's other current assets for the quarter that ended in Mar. 2024 was $14.68 Mil.
Kymera Therapeutics's quarterly other current assets declined from Sep. 2023 ($14.09 Mil) to Dec. 2023 ($11.67 Mil) but then increased from Dec. 2023 ($11.67 Mil) to Mar. 2024 ($14.68Mil).
Kymera Therapeutics's annual other current assets increased from Dec. 2021 ($8.72 Mil) to Dec. 2022 ($9.71 Mil) increased from Dec. 2022 ($9.71 Mil) to Dec. 2023 ($11.67 Mil).
The historical data trend for Kymera Therapeutics's Other Current Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics Annual Data | |||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Other Current Assets | Get a 7-Day Free Trial | 0.89 | 4.70 | 8.72 | 9.71 | 11.67 |
Kymera Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Other Current Assets | Get a 7-Day Free Trial | 11.35 | 13.71 | 14.09 | 11.67 | 14.68 |
Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:
The assets grouped under other current assets are most commonly:
Some companies can and do choose to report each of these items separately.
Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.
Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.
Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.
Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.
There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.
At most companies, other current assets are a small and unimportant part of the total balance sheet.
Thank you for viewing the detailed overview of Kymera Therapeutics's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Jeffrey W. Albers | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Ellen Chiniara | officer: Chief Legal Officer | 51 SAWYER ROAD, SUITE 200, WALTHAM MA 02453 |
Biotechnology Value Fund L P | other: See Explanation of Responses | 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104 |
Jeremy G Chadwick | officer: Chief Operating Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
Bruce N. Jacobs | officer: Chief Financial Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Bruce Booth | director | 890 WINTER STREET, SUITE 320, WALTHAM MA 02451 |
Atlas Venture Fund X, L.p. | 10 percent owner | 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139 |
Victor Sandor | director | C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301 |
Leigh Morgan | director | KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN MA 02472 |
John Maraganore | director | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Nello Mainolfi | director, officer: President and CEO | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Jared Gollob | officer: Chief Medical Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Richard Chesworth | officer: Chief Scientific Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
Atlas Venture Associates X, L.p. | 10 percent owner | 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139 |
Elaine Caughey | officer: Chief Business Officer | C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS, SUITE 230, WATERTOWN MA 02472 |
From GuruFocus
By Marketwired • 08-03-2023
By Stock market mentor Stock market mentor • 01-10-2023
By Marketwired • 06-22-2023
By Value_Insider Value_Insider • 12-11-2022
By Marketwired • 07-27-2023
By sperokesalga sperokesalga • 02-23-2023
By Stock market mentor Stock market mentor • 01-03-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocus Research • 11-02-2023
By Marketwired • 10-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.